Podcast: ‘Pharma Is Not Just A Cost Component’ – Showcasing Value As Well As Innovation

Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.    

In Vivo Podcast
• Source: Shutterstock

“It cannot be that we only innovate in science and that we can’t innovate in the ways we do business and how we shape health care systems.” In this latest instalment of the In Vivo podcast, Claus Zieler, chief commercial officer at Astellas Pharma, puts out a call to action for industry to better collaborate with regulators to improve access to medicines in a more efficient manner.

Zieler discusses the shift in health care models from chronic disease management to potential one-off treatments, and the impact of...

More from Market Access

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.